←Infectious Disease
Community-acquired pneumonia
📚
📚 Library › 🦠 Infectious Disease › Pneumonia
🫁

Community-acquired pneumonia

Severity scores, empiric antibiotics, MRSA/Pseudomonas rules, steroids for severe CAP and short courses (ATS 2025).

CAPCURB-65PSIsteroidsATS 2025
🗓️ Reviewed 2026-11-18 · ⏱️ 3 min read · 📖 2025 ATS CAP guideline update · 2019 ATS/IDSA CAP guideline · 2016 IDSA/ATS HAP/VAP
🧠 Pathophysiology in 60 seconds🔎 Diagnosis💊 Management⚠️ Pitfalls🎓 Board corner📚 References
⚡ Bottom line — first hour
  • Severity decides site of care: PSI or CURB-65 + judgment; IDSA/ATS severe criteria for ICU.
  • Non-severe inpatient: ceftriaxone + azithromycin (or doxycycline), or a respiratory fluoroquinolone alone.
  • Cover MRSA/Pseudomonas only if prior isolate — or recent hospitalization + IV antibiotics and local risk. Get cultures + nasal MRSA PCR and de-escalate.
  • Severe CAP → add hydrocortisone (ATS 2025). No steroids for non-severe CAP.
  • Short courses: stable by day 3 → 3–5 days total is enough for non-severe CAP. Longer for severe, S. aureus, Pseudomonas, empyema.

🧠 Pathophysiology in 60 seconds

⌄
  • Micro-aspiration of oropharyngeal flora (or inhaled droplets) beats the lung's defenses → alveolar inflammation → exudate fills alveoli → V/Q mismatch and shunt → hypoxemia.
  • Common bugs: S. pneumoniae, H. influenzae, M. catarrhalis, atypicals (Mycoplasma, Chlamydophila, Legionella), viruses (influenza, RSV, SARS-CoV-2, hMPV). S. aureus after influenza.

🔎 Diagnosis

⌄
  • New infiltrate + symptoms (fever, cough, dyspnea, pleuritic pain, crackles).
  • Lung ultrasound is an acceptable alternative to CXR where expertise exists (ATS 2025).
  • Inpatients: blood cultures + sputum culture if severe or MRSA/PsA risk; Legionella + pneumococcal urine antigens if severe; respiratory viral PCR; nasal MRSA PCR if MRSA coverage started.
  • Procalcitonin: does not decide whether to start antibiotics.
CURB-65 (1 each)
Confusion
Urea >19 mg/dL (BUN >7 mmol/L)
RR ≥30
BP SBP <90 or DBP ≤60
Age ≥65
0–1 home · 2 admit · ≥3 consider ICU

Severe CAP (IDSA/ATS): 1 major (septic shock on pressors, or mechanical ventilation) or ≥3 minor (RR ≥30, P/F ≤250, multilobar, confusion, BUN ≥20, WBC <4 k, platelets <100 k, T <36 °C, hypotension needing fluids).

💊 Management

⌄
Setting Regimen
Ward, non-severe Ceftriaxone 1–2 g daily + azithromycin 500 mg daily (or doxycycline 100 mg BID) · or levofloxacin 750 mg / moxifloxacin 400 mg
Severe / ICU β-lactam + azithromycin (preferred) or + respiratory FQ
Prior MRSA (resp) Add vancomycin or linezolid → stop if nasal PCR & cultures negative
Prior Pseudomonas (resp) Cefepime / pip-tazo / meropenem
Aspiration No routine anaerobic coverage unless abscess or empyema
Influenza positive Oseltamivir too
  • Severe CAP: hydrocortisone 200 mg/day (e.g., 50 mg IV q6h or infusion) for 4–7 days, taper by response (CAPE COD regimen).
  • Non-severe CAP: do not give systemic steroids (strong recommendation).
  • Avoid in influenza pneumonia; caution in aspergillosis risk.
  • Switch to PO when improving, afebrile, eating, hemodynamically stable.
  • Non-severe, clinically stable by day 3 → minimum 3 days; ~5 days total is acceptable.
  • Severe CAP, MRSA, Pseudomonas, empyema, abscess → individualize (≥7 days).
  • Positive viral test, hospitalized → ATS 2025 suggests still giving antibacterial therapy (co-infection is hard to exclude); reassess early and stop if the bacterial workup is negative and the patient improves. Outpatients with a virus and no major comorbidity can often skip antibiotics.

⚠️ Pitfalls

⌄
  • Reflex "HCAP" vancomycin + pip-tazo (HCAP no longer exists).
  • Missing empyema in a slow responder → ultrasound/CT, tap.
  • 10–14 day courses "to be safe."
  • Not checking QTc with azithro/FQ combos.

🎓 Board corner

⌄
Stem Answer
CAP, ward, no MRSA/PsA risk Ceftriaxone + azithromycin
Severe CAP on pressors β-lactam + macrolide + hydrocortisone
Necrotizing pneumonia after influenza S. aureus (MRSA) → vancomycin/linezolid
Hyponatremia, diarrhea, high fever, confusion Legionella → urine antigen, azithro/levofloxacin
Still febrile day 4, dull base Parapneumonic effusion → tap

📚 References

⌄
  • Jones BE, Ramirez JA, et al. Diagnosis and Management of CAP. ATS Clinical Practice Guideline. AJRCCM. 2025 (endorsed by ATS).
  • Metlay JP, et al. 2019 ATS/IDSA CAP guideline. AJRCCM. 2019;200:e45.
  • Dequin PF, et al. CAPE COD. NEJM. 2023;388:1931.
↩︎ Back to 🦠 Infectious Disease